INDOUS Q1 FY27 results at a glance
INDO US BIOTECH LTD Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹32.99 cr |
|---|
| Revenue YoY | +7.2% |
|---|
| Operating profit | ₹3.69 cr |
|---|
| Operating margin | 11.2% |
|---|
| Net profit | ₹3.04 cr |
|---|
| Net profit YoY | -35.4% |
|---|
| Net profit QoQ | +54.0% |
|---|
| Net margin | 9.2% |
|---|
| Basic EPS | ₹1.51 |
|---|
| TTM revenue | ₹113 cr |
|---|
| TTM net profit | ₹11.46 cr |
|---|
| TTM net margin | 10.2% |
|---|
INDOUS Q1 FY27 results: what the numbers say
INDO US BIOTECH LTD (INDOUS) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹32.99 cr and a net profit of ₹3.04 cr, translating into earnings per share of ₹1.51.
Compared with the same quarter a year earlier, revenue grew by +7.2% and net profit declined strongly by -35.4%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹3.69 cr, an operating margin of 11.2% versus 17.1% a year ago — a contraction of 5.9 percentage points.
INDOUS quarter-wise results table
Revenue
₹32.99 cr
+7.2% YoY
Net profit
₹3.04 cr
-35.4% YoY
Operating profit
₹3.69 cr
-29.9% YoY
INDO US BIOTECH LTD (INDOUS) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹32.99 cr | ₹3.69 cr | ₹3.04 cr | 11.2% | 9.2% | ₹1.51 | -35.4% | +54.0% |
| Q4 FY262026-03-31 | ₹26.02 cr | ₹2.96 cr | ₹1.97 cr | 11.4% | 7.6% | ₹0.98 | — | -34.2% |
| Q3 FY262025-12-31 | ₹22.8 cr | ₹3.93 cr | ₹3 cr | 17.2% | 13.1% | ₹1.49 | — | -13.2% |
| Q2 FY262025-09-30 | ₹30.85 cr | ₹3.96 cr | ₹3.45 cr | 12.8% | 11.2% | ₹1.72 | — | -26.6% |
| Q1 FY262025-06-30 | ₹30.77 cr | ₹5.27 cr | ₹4.7 cr | 17.1% | 15.3% | ₹2.35 | — | — |
| TTM (last 4 quarters) | ₹113 cr | ₹14.53 cr | ₹11.46 cr | 12.9% | 10.2% | ₹5.70 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
INDOUS quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
INDO US BIOTECH LTD quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹32.99 cr | ₹26.02 cr | ₹22.8 cr | ₹30.85 cr | ₹30.77 cr |
|---|
| Total expenses | ₹29.29 cr | ₹23.07 cr | ₹18.87 cr | ₹26.89 cr | ₹25.5 cr |
|---|
| Gross profit | ₹6.96 cr | ₹7.61 cr | ₹6.82 cr | ₹7.1 cr | ₹8.65 cr |
|---|
| Operating profit (EBIT) | ₹3.69 cr | ₹2.96 cr | ₹3.93 cr | ₹3.96 cr | ₹5.27 cr |
|---|
| Operating margin | 11.2% | 11.4% | 17.2% | 12.8% | 17.1% |
|---|
| Interest cost | ₹0.74 cr | ₹0.6 cr | ₹0.77 cr | ₹0.42 cr | ₹0.45 cr |
|---|
| Profit before tax | ₹3.08 cr | ₹2.38 cr | ₹3.16 cr | ₹3.56 cr | ₹4.82 cr |
|---|
| Tax expense | ₹0.04 cr | ₹0.41 cr | ₹0.17 cr | ₹0.11 cr | ₹0.12 cr |
|---|
| Effective tax rate | 1.3% | 17.1% | 5.3% | 3.0% | 2.4% |
|---|
| Net profit (PAT) | ₹3.04 cr | ₹1.97 cr | ₹3 cr | ₹3.45 cr | ₹4.7 cr |
|---|
| Net profit margin | 9.2% | 7.6% | 13.1% | 11.2% | 15.3% |
|---|
| Basic EPS | ₹1.51 | ₹0.98 | ₹1.49 | ₹1.72 | ₹2.35 |
|---|
| Diluted EPS | ₹1.51 | ₹0.98 | ₹1.49 | ₹1.72 | ₹2.35 |
|---|
INDOUS results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +7.2% | — | — | — | — |
|---|
| Revenue QoQ | +26.8% | +14.2% | -26.1% | +0.2% | — |
|---|
| Operating profit YoY | -29.9% | — | — | — | — |
|---|
| Operating profit QoQ | +24.8% | -24.6% | -0.8% | -24.9% | — |
|---|
| Net profit YoY | -35.4% | — | — | — | — |
|---|
| Net profit QoQ | +54.0% | -34.2% | -13.2% | -26.6% | — |
|---|
| EPS YoY | -35.7% | — | — | — | — |
|---|
| EPS QoQ | +54.1% | -34.2% | -13.4% | -26.8% | — |
|---|
INDOUS annual results history
Full-year performance for INDO US BIOTECH LTD, useful for reading each quarter in context.
INDO US BIOTECH LTD annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹110 cr | ₹104 cr | ₹72.84 cr | ₹61.74 cr |
|---|
| Total expenses | ₹94.21 cr | ₹85.83 cr | ₹62.47 cr | ₹53.16 cr |
|---|
| Gross profit | ₹28.36 cr | ₹29.47 cr | ₹20.64 cr | ₹16 cr |
|---|
| Operating profit (EBIT) | ₹16.23 cr | ₹18.01 cr | ₹10.36 cr | ₹8.59 cr |
|---|
| Operating margin | 14.7% | 17.3% | 14.2% | 13.9% |
|---|
| Interest cost | ₹2.14 cr | ₹1.44 cr | ₹1.41 cr | ₹1.12 cr |
|---|
| Profit before tax | ₹13.92 cr | ₹16.53 cr | ₹8.79 cr | ₹7.39 cr |
|---|
| Tax expense | ₹0.8 cr | ₹0.26 cr | ₹0.55 cr | ₹0.15 cr |
|---|
| Effective tax rate | 5.7% | 1.6% | 6.3% | 2.0% |
|---|
| Net profit (PAT) | ₹13.12 cr | ₹16.27 cr | ₹8.24 cr | ₹7.24 cr |
|---|
| Net profit margin | 11.9% | 15.7% | 11.3% | 11.7% |
|---|
| Basic EPS | ₹6.54 | ₹8.11 | ₹4.11 | ₹3.75 |
|---|
| Diluted EPS | ₹6.54 | ₹8.11 | ₹4.11 | ₹3.75 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹32.99 cr against ₹30.77 cr in Q1 FY26, and ₹26.02 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +26.8%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹29.29 cr, or 88.8% of revenue, with operating profit declined -29.9% year on year.
Margins, tax and profitability
Net profit of ₹3.04 cr works out to a net margin of 9.2% compared with 15.3% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, INDO US BIOTECH LTD reported profit before tax of ₹3.08 cr, a tax charge of ₹0.04 cr (effective rate 1.3%), interest cost of ₹0.74 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹1.97 cr in Q4 FY26 to ₹3.04 cr in Q1 FY27, a change of +54.0%.
Trailing twelve months and annual context
Across the trailing four quarters INDO US BIOTECH LTD has generated revenue of ₹113 cr and net profit of ₹11.46 cr, a trailing net margin of 10.2%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹110 cr with net profit of ₹13.12 cr and EPS of ₹6.54, versus the prior year where revenue grew +6.4% and profit declined -19.3%.
What to watch in the next INDOUS quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
INDO US BIOTECH LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
INDOUS results coverage
No results report published for INDOUS yet — our desk covers each quarter within minutes of the filing.
INDOUS quarterly results FAQs
What were INDO US BIOTECH LTD (INDOUS) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), INDO US BIOTECH LTD reported revenue of ₹32.99 cr and net profit of ₹3.04 cr, a change of -35.4% year on year on +7.2% revenue growth. EPS stood at ₹1.51.
What is INDOUS profit margin in Q1 FY27?
INDO US BIOTECH LTD posted a net profit margin of 9.2% and an operating margin of 11.2% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹113 cr and net profit ₹11.46 cr.
Did INDOUS results beat the previous quarter?
INDO US BIOTECH LTD net profit changed +54.0% quarter on quarter, from ₹1.97 cr in Q4 FY26 to ₹3.04 cr in Q1 FY27.
When are INDO US BIOTECH LTD (INDOUS) quarterly results?
INDO US BIOTECH LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see INDOUS latest quarterly results?
Results coverage for INDOUS will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the INDOUS stock page.
What is INDO US BIOTECH LTD annual revenue and profit?
For FY26, INDO US BIOTECH LTD reported full-year revenue of ₹110 cr and net profit of ₹13.12 cr, with EPS of ₹6.54.
How many quarterly results has INDOUS declared recently?
Past results dates for INDOUS will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
